share_log

Redhill Biopharma | CORRESP: CORRESP

Redhill Biopharma | CORRESP: CORRESP

Redhill Biopharma | CORRESP：信函
SEC announcement ·  02/15 12:59
Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., an Israel-based pharmaceutical company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-1. The request, filed on February 15, 2024, seeks to advance the effective date to 4:30 p.m. Eastern Time on the same day, or as soon as possible thereafter. This action follows the initial filing of the Registration Statement on February 9, 2024, under file number 333-276979. RedHill Biopharma has designated its counsel, Haynes and Boone, LLP, to receive notification of the Registration Statement's effectiveness via telephone, with a follow-up confirmation in writing.
RedHill Biopharma Ltd., an Israel-based pharmaceutical company, has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-1. The request, filed on February 15, 2024, seeks to advance the effective date to 4:30 p.m. Eastern Time on the same day, or as soon as possible thereafter. This action follows the initial filing of the Registration Statement on February 9, 2024, under file number 333-276979. RedHill Biopharma has designated its counsel, Haynes and Boone, LLP, to receive notification of the Registration Statement's effectiveness via telephone, with a follow-up confirmation in writing.
总部位于以色列的制药公司RedHill Biopharma Ltd. 已正式要求美国证券交易委员会（SEC）加快其F-1表格注册声明的生效日期。该请求于2024年2月15日提出，旨在将生效日期提前至美国东部时间当天下午 4:30，或之后尽快提前。该行动是在2024年2月9日首次提交注册声明之后采取的，文件编号为333-276979。RedHill Biopharma已指定其律师Haynes and Boone, LLP通过电话接收注册声明的生效通知，并附上后续书面确认。
总部位于以色列的制药公司RedHill Biopharma Ltd. 已正式要求美国证券交易委员会（SEC）加快其F-1表格注册声明的生效日期。该请求于2024年2月15日提出，旨在将生效日期提前至美国东部时间当天下午 4:30，或之后尽快提前。该行动是在2024年2月9日首次提交注册声明之后采取的，文件编号为333-276979。RedHill Biopharma已指定其律师Haynes and Boone, LLP通过电话接收注册声明的生效通知，并附上后续书面确认。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息